[{"id":"c72ecd8f-9c23-45c8-aceb-c2281207ef26","acronym":"","url":"https://clinicaltrials.gov/study/NCT07141771","created_at":"2025-08-30T13:51:58.696Z","updated_at":"2025-08-30T13:51:58.696Z","phase":"Phase 1/2","brief_title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","source_id_and_acronym":"NCT07141771","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • temozolomide • etoposide IV • irinotecan • topotecan • AiRuiYi (fluzoparib) • Zepzelca (lurbinectedin) • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/31/2025","start_date":" 12/31/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-08-26"},{"id":"4bf912ed-2f96-4d90-aef7-e45022410420","acronym":"","url":"https://clinicaltrials.gov/study/NCT00186888","created_at":"2025-07-19T13:43:51.175Z","updated_at":"2025-07-19T13:43:51.175Z","phase":"Phase 3","brief_title":"Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","source_id_and_acronym":"NCT00186888","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" ABCG2 • CYP3A4","pipe":"","alterations":" ","tags":["ABCG2 • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 04/07/2005","start_date":" 04/07/2005","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 11/12/2024","study_completion_date":" 11/12/2024","last_update_posted":"2025-04-15"},{"id":"52425dc1-74c8-49b8-8efe-2388d72e2562","acronym":"","url":"https://clinicaltrials.gov/study/NCT06172296","created_at":"2023-12-15T20:18:48.678Z","updated_at":"2025-02-25T14:04:06.256Z","phase":"Phase 3","brief_title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","source_id_and_acronym":"NCT06172296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • TERT • MYCN","pipe":"","alterations":" ","tags":["ALK • TERT • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 478","initiation":"Initiation: 04/19/2024","start_date":" 04/19/2024","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-19"},{"id":"48a9756f-4a13-44e2-87fd-34412cf0be4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05990738","created_at":"2023-08-14T14:10:29.956Z","updated_at":"2025-02-25T14:09:58.704Z","phase":"Phase 1","brief_title":"DAREONTM-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy","source_id_and_acronym":"NCT05990738","lead_sponsor":"Boehringer Ingelheim","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e topotecan • obrixtamig (BI 764532)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 02/14/2024","start_date":" 02/14/2024","primary_txt":" Primary completion: 01/21/2026","primary_completion_date":" 01/21/2026","study_txt":" Completion: 11/21/2026","study_completion_date":" 11/21/2026","last_update_posted":"2025-02-18"},{"id":"624dd6dc-cc83-4a6f-bc36-82aa836ef4f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05429502","created_at":"2022-06-23T16:00:07.143Z","updated_at":"2025-02-25T14:08:56.594Z","phase":"Phase 1/2","brief_title":"Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors","source_id_and_acronym":"NCT05429502","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MYCN • SMARCB1","pipe":" | ","alterations":" IDH wild-type","tags":["MYCN • SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Kisqali (ribociclib) • topotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 231","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 10/15/2027","primary_completion_date":" 10/15/2027","study_txt":" Completion: 01/28/2028","study_completion_date":" 01/28/2028","last_update_posted":"2025-02-17"},{"id":"4b1b80e8-bcd8-4a78-8ae1-fe238c0362b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126916","created_at":"2021-01-18T15:24:54.957Z","updated_at":"2025-02-25T15:10:35.328Z","phase":"Phase 3","brief_title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","source_id_and_acronym":"NCT03126916","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 724","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"a5031666-4a50-4613-ab67-b57e264769e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04322318","created_at":"2023-11-21T20:16:14.157Z","updated_at":"2025-02-25T15:11:30.447Z","phase":"Phase 2","brief_title":"A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT","source_id_and_acronym":"NCT04322318","lead_sponsor":"Children's Oncology Group","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 221","initiation":"Initiation: 10/19/2020","start_date":" 10/19/2020","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-13"},{"id":"79754c99-3751-46a3-9cbb-21442fd0c3e5","acronym":"NRG-GY023","url":"https://clinicaltrials.gov/study/NCT04739800","created_at":"2021-02-05T13:56:26.400Z","updated_at":"2025-02-25T15:26:41.757Z","phase":"Phase 2","brief_title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","source_id_and_acronym":"NCT04739800 - NRG-GY023","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["PD-L1 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/10/2021","start_date":" 06/10/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 06/14/2025","study_completion_date":" 06/14/2025","last_update_posted":"2025-02-10"},{"id":"a3c29634-7fe3-458b-95a0-a95c7ed454c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101788","created_at":"2021-01-18T09:42:39.713Z","updated_at":"2025-02-25T16:36:20.602Z","phase":"Phase 2/3","brief_title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","source_id_and_acronym":"NCT02101788","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 02/27/2014","start_date":" 02/27/2014","primary_txt":" Primary completion: 04/04/2019","primary_completion_date":" 04/04/2019","study_txt":" Completion: 10/11/2025","study_completion_date":" 10/11/2025","last_update_posted":"2025-02-06"},{"id":"d2101305-ed21-4d8c-a684-029721d03d01","acronym":"NCI-2022-03215","url":"https://clinicaltrials.gov/study/NCT05353439","created_at":"2022-04-29T11:55:38.458Z","updated_at":"2025-02-25T16:26:50.630Z","phase":"Phase 1","brief_title":"Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer","source_id_and_acronym":"NCT05353439 - NCI-2022-03215","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tazverik (tazemetostat) • topotecan • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 60","initiation":"Initiation: 07/27/2022","start_date":" 07/27/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-01-28"},{"id":"cd892406-57e9-4ba5-95af-1d838d031b7c","acronym":"CA116-001","url":"https://clinicaltrials.gov/study/NCT05613088","created_at":"2023-12-07T21:16:29.597Z","updated_at":"2025-02-25T13:36:17.948Z","phase":"Phase 2","brief_title":"A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT05613088 - CA116-001","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • pegylated liposomal doxorubicin • topotecan • farletuzumab ecteribulin (MORAb-202)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 06/05/2024","primary_completion_date":" 06/05/2024","study_txt":" Completion: 10/11/2026","study_completion_date":" 10/11/2026","last_update_posted":"2024-11-21"},{"id":"13b4bbab-cc06-4064-873f-d9af6714b5de","acronym":"SJATRT","url":"https://clinicaltrials.gov/study/NCT02114229","created_at":"2021-01-18T09:46:59.452Z","updated_at":"2025-02-25T14:56:56.615Z","phase":"Phase 2","brief_title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","source_id_and_acronym":"NCT02114229 - SJATRT","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • topotecan • alisertib (MLN8237) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 05/14/2014","start_date":" 05/14/2014","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-10-31"},{"id":"c2c40e25-bf03-4412-bf0e-9712fe410547","acronym":"","url":"https://clinicaltrials.gov/study/NCT04947501","created_at":"2021-07-01T14:54:45.053Z","updated_at":"2024-07-02T16:34:27.282Z","phase":"Phase 1","brief_title":"A Study of N9 Chemotherapy in Children With Neuroblastoma","source_id_and_acronym":"NCT04947501","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • topotecan • mesna • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 06/22/2025","primary_completion_date":" 06/22/2025","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2024-06-11"},{"id":"d9dd8a9e-c9dc-461e-aece-5bc7f49d536e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03709680","created_at":"2021-11-09T18:05:08.609Z","updated_at":"2024-07-02T16:35:02.132Z","phase":"Phase 1/2","brief_title":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","source_id_and_acronym":"NCT03709680","lead_sponsor":"Pfizer","biomarkers":" EWSR1 • FUS","pipe":"","alterations":" ","tags":["EWSR1 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • temozolomide • cyclophosphamide • irinotecan • topotecan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 05/24/2019","start_date":" 05/24/2019","primary_txt":" Primary completion: 06/24/2024","primary_completion_date":" 06/24/2024","study_txt":" Completion: 02/25/2025","study_completion_date":" 02/25/2025","last_update_posted":"2024-05-22"},{"id":"4c69c646-417d-429d-bb95-ea9731d61b06","acronym":"COCOS","url":"https://clinicaltrials.gov/study/NCT02502266","created_at":"2021-01-18T12:04:33.243Z","updated_at":"2024-07-02T16:35:02.420Z","phase":"Phase 2/3","brief_title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","source_id_and_acronym":"NCT02502266 - COCOS","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 562","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-05-21"},{"id":"ed745a1a-e25b-481e-9a43-45f739d28d5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04239092","created_at":"2021-01-18T20:36:34.133Z","updated_at":"2024-07-02T16:35:03.671Z","phase":"Phase 1","brief_title":"9-ING-41 in Pediatric Patients With Refractory Malignancies.","source_id_and_acronym":"NCT04239092","lead_sponsor":"Actuate Therapeutics Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • cyclophosphamide • irinotecan • topotecan • elraglusib (9-ING-41) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-15"},{"id":"95fe996a-08c8-4bbd-9a80-6d6d99bc679d","acronym":"REFRaME-O1","url":"https://clinicaltrials.gov/study/NCT05870748","created_at":"2023-05-23T16:06:11.980Z","updated_at":"2024-07-02T16:35:08.676Z","phase":"Phase 2/3","brief_title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","source_id_and_acronym":"NCT05870748 - REFRaME-O1","lead_sponsor":"Sutro Biopharma, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression • FOLR1 positive","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • FOLR1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-19"},{"id":"0130cadc-804e-436f-a2b2-19a2f539a6a6","acronym":"NCI-2018-03732","url":"https://clinicaltrials.gov/study/NCT03786783","created_at":"2021-01-18T18:43:54.532Z","updated_at":"2024-07-02T16:35:09.101Z","phase":"Phase 2","brief_title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","source_id_and_acronym":"NCT03786783 - NCI-2018-03732","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYCN • IL6 • CXCL9","pipe":" | ","alterations":" MYCN amplification • IL6 expression","tags":["MYCN • IL6 • CXCL9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/04/2019","start_date":" 03/04/2019","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-04-17"},{"id":"ba5e9c1f-9156-4368-acb2-f775396afb8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04029688","created_at":"2021-01-18T19:46:44.421Z","updated_at":"2024-07-02T16:35:12.360Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors","source_id_and_acronym":"NCT04029688","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • cyclophosphamide • topotecan • idasanutlin (RG7388) • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 01/27/2020","start_date":" 01/27/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-03-29"},{"id":"519407a2-e161-4bce-9dc1-be6550116e9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800587","created_at":"2023-04-05T14:03:42.889Z","updated_at":"2024-07-02T16:35:12.781Z","phase":"Phase 2","brief_title":"Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer","source_id_and_acronym":"NCT05800587","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • docetaxel • albumin-bound paclitaxel • pemetrexed • etoposide IV • irinotecan • topotecan • Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 02/22/2023","start_date":" 02/22/2023","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2024-03-26"},{"id":"db508520-4ea9-4c84-8d31-9c56429ac8f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01798004","created_at":"2021-01-18T07:57:29.532Z","updated_at":"2024-07-02T16:35:15.000Z","phase":"Phase 1","brief_title":"Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","source_id_and_acronym":"NCT01798004","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification • MYCN expression","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • busulfan • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/08/2013","start_date":" 04/08/2013","primary_txt":" Primary completion: 07/28/2015","primary_completion_date":" 07/28/2015","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-13"},{"id":"c14e2d3d-2408-48c9-8ec6-22c81595ada5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02487095","created_at":"2021-01-18T11:59:05.036Z","updated_at":"2024-07-02T16:35:16.360Z","phase":"Phase 1/2","brief_title":"Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers","source_id_and_acronym":"NCT02487095","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • topotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 07/30/2015","start_date":" 07/30/2015","primary_txt":" Primary completion: 02/24/2021","primary_completion_date":" 02/24/2021","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2024-03-05"},{"id":"f0ba29c7-b73b-4be0-abe3-ad073e67bec5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01012817","created_at":"2021-01-18T03:58:12.492Z","updated_at":"2024-07-02T16:35:16.316Z","phase":"Phase 1/2","brief_title":"Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT01012817","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • topotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/03/2009","start_date":" 11/03/2009","primary_txt":" Primary completion: 01/13/2019","primary_completion_date":" 01/13/2019","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2024-03-05"},{"id":"7442a163-6eec-47a9-bb41-9d083af1512d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01857934","created_at":"2021-01-18T08:18:15.837Z","updated_at":"2024-07-02T16:35:23.492Z","phase":"Phase 2","brief_title":"Therapy for Children With Advanced Stage Neuroblastoma","source_id_and_acronym":"NCT01857934","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • cyclophosphamide intravenous • humanised dinutuximab (Hu14.18K322A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 07/05/2013","start_date":" 07/05/2013","primary_txt":" Primary completion: 10/21/2021","primary_completion_date":" 10/21/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-15"}]